Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06251934 · ClinicalTrials.gov registry record
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 785
- Enrollment target
NCT06251934: Completed study, sponsored by Novartis Pharmaceuticals.
NCT06251934 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 785 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06251934 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 785 participants
- Enrollment target
Study Summary
This was a retrospective, longitudinal, observational study conducted using the Flatiron Health electronic health record (EHR)-derived database. BRAF+ advanced or metastatic (i.e., stage III or IV) melanoma patients treated at oncology practices across the US were identified for potential inclusion. All included patients were aged ≥18 years and required to have a diagnosis of melanoma (International Classification of Diseases (ICD)-9 172.x \& ICD-10 C43 or D03x), a pathologic unresectable stage III or IV diagnosis, subsequent first-line (1L) treatment with either immunotherapy (IO) (nivolumab, pembrolizumab, ipilimumab + nivolumab) or targeted therapy (TT) dafratenib + trametinib (dab/tram) on or after 01 January 2014, and evidence of a BRAF-positive result at any point in time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 785 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2022-11-24 |
What the finished NCT06251934 record still lists
NCT06251934 is an observational study that tracks outcomes without assigning an intervention. The registered 785 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06251934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06251934 about?
NCT06251934 is a clinical study titled "Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma". This was a retrospective, longitudinal, observational study conducted using the Flatiron Health electronic health record (EHR)-derived database. BRAF+ advanced or metastatic (i.e., stage III or IV) melanoma patients treated at oncology practices across the US were identified for potential inclusion....
What is the current status of trial NCT06251934?
This trial is currently completed. The enrollment target is 785 participants. The study started on 2022-09-28. Estimated completion is 2022-11-24.
Who is sponsoring clinical trial NCT06251934?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06498128 · 785 participants
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- NCT07276724 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
- NCT07359846 · 786 participants · Phase 3
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
- NCT06118723 · 784 participants
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI